BrainStorm Cell Therapeutics Poised for Major Rebound With Upcoming AdCom Meeting For ALS Treatment NurOwn

Trending News ☀️

BRAINSTORM CELL THERAPEUTICS ($NASDAQ:BCLI) is a biotechnology company dedicated to developing innovative autologous cellular therapeutics for the treatment of neurodegenerative diseases. The company’s primary focus is on its NurOwn platform of cellular therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The upcoming AdCom Meeting for ALS Treatment NurOwn could potentially be the start of a major rebound for BRAINSTORM CELL THERAPEUTICS. The AdCom Meeting will review the efficacy and safety of NurOwn in treating ALS, which could lead to its potential approval as a novel therapy. This would be a major breakthrough for the company as well as for ALS patients, potentially transforming the lives of those affected by the disease.

If approved, it could be a major milestone in the company’s ongoing efforts to develop innovative treatments for neurodegenerative diseases. With the potential approval of NurOwn as a novel therapy, the company could experience a significant increase in stock value and could be on track for long-term success. Investors should keep an eye out for the results of the AdCom Meeting, as it could potentially be a major game-changer for BRAINSTORM CELL THERAPEUTICS.

Price History

On Thursday, BRAINSTORM CELL THERAPEUTICS stock opened at $2.4 and closed at $2.5, up by 2.5% from last closing price of $2.4. This marked the highest close since April and indicated that investors are cautiously optimistic about the outcome of the AdCom meeting. The meeting is scheduled for June 10th, and investors are hopeful that the committee will recommend approval of NurOwn for the treatment of ALS. If the AdCom approves NurOwn’s use for ALS, BRAINSTORM CELL THERAPEUTICS could see a significant increase in share price as well as increased demand for their product. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for BCLI. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for BCLI. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for BCLI. More…

Key Ratios Snapshot

Some of the financial key ratios for BCLI are shown below. More…

Analysis

As GoodWhale, we have done a comprehensive analysis of BRAINSTORM CELL THERAPEUTICS’ fundamentals. Based on our Star Chart, BRAINSTORM CELL THERAPEUTICS is categorized as an ‘elephant’, which is a type of company that holds a large amount of assets after subtracting its liabilities. Such companies may attract various types of investors. When we further examine BRAINSTORM CELL THERAPEUTICS, we see that it is strong in some areas such as capital structure and liquidity, but weaker in others such as dividend, growth, and profitability. Additionally, our health score for BRAINSTORM CELL THERAPEUTICS is 2/10, which suggests that its cashflows and debt are not performing well and it is less likely to be resilient during difficult times without the risk of bankruptcy. More…

Peers

The competition in the cell therapy market is heating up as more and more companies are vying for a piece of the pie. Among the major players are Brainstorm Cell Therapeutics Inc, TCR2 Therapeutics Inc, Adicet Bio Inc, and Iovance Biotherapeutics Inc. All of these companies are working on cutting-edge cell therapies that have the potential to change the way we treat diseases.

– TCR2 Therapeutics Inc ($NASDAQ:TCRR)

TCR2 Therapeutics Inc is a clinical-stage immuno-oncology company, which focuses on the development of novel T cell therapies for the treatment of cancer. The company has a market cap of $54.51M and a ROE of -24.78%. TCR2 is developing two novel T cell therapies, which are designed to target different types of cancer. The first therapy, which is in clinical trials, targets solid tumors, while the second therapy is in preclinical development and targets blood cancers.

– Adicet Bio Inc ($NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biopharmaceutical company focused on the development of immune cell therapies for cancer and other diseases. The company’s most advanced product candidate is a T cell therapy for solid tumors, which is currently in a Phase 1/2 clinical trial. The company has a market cap of $871.6M as of 2022 and a Return on Equity of -11.39%.

– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)

Iovance Biotherapeutics Inc is a late-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products based on tumor-infiltrating lymphocyte (TIL) technology.

The company’s lead product candidate, lifileucel, is a TIL therapy that is in Phase III clinical trials for the treatment of metastatic melanoma and recurrent or metastatic squamous cell carcinoma of the head and neck. Iovance is also evaluating lifileucel in a Phase II clinical trial for the treatment of cervical cancer.

Iovance has a market cap of 1.19B as of 2022. The company’s Return on Equity is -56.45%.

Summary

BrainStorm Cell Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel autologous cellular treatments for neurological diseases. Recent news has been positive, with the U.S. Food and Drug Administration granting Breakthrough Therapy designation for their NurOwn treatment for ALS (Amyotrophic Lateral Sclerosis). The upcoming AdCom meeting is expected to be a major factor in determining the progress of the NurOwn program, and could potentially mark the start of a long-term turnaround for the company.

Investor sentiment appears to be cautiously optimistic, as the company’s share price has risen steadily in recent trading sessions. Analysts are anticipating a favorable outcome at the AdCom meeting and are recommending that investors take advantage of potential upside potential by buying shares in BrainStorm.